MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?

    A.S Nordvig, R.N Alcalay, J.M Berger, K. Marder, G. Karsenty, A. Wang (New York, NY, USA)

    Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…
  • MDS Virtual Congress 2020

    Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease

    S. Grigoriou, S. Christiansson, P. Odin, M.A Cenci (Lund, Sweden)

    Objective: To investigate possible differences in phenomenology and temporal profile of dyskinesias in patients with Parkinson’s disease (PD) after challenge doses with levodopa alone or…
  • MDS Virtual Congress 2020

    Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience

    Y. Sucullu Karadag (Ankara, Turkey)

    Objective: This study is aimed to investigate the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish movement disorder center.…
  • MDS Virtual Congress 2020

    Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy

    T. Birnberg, G. Smania, M. Bjornsson, N. Jonsson, R. Case, S. Oren, L. Adar, M. Karlsson (Rehovot, Israel)

    Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…
  • MDS Virtual Congress 2020

    Monitoring electrophysiological recordings in patients with LCIJ therapy

    D. Gunal, H. Ozden, S. Irmak, K. Uluc (Istanbul, Turkey)

    Objective: Levodopa carbidopa intestinal jel (LCIJ) treatment for advanced Parkinson’s disease patients is live-saving for the appropriate patients, however follow up of the patients has…
  • MDS Virtual Congress 2020

    Levodopa induced changes of tongue body movements during speech production

    T. Thies, D. Mücke, R. Dano, M.. Barbe (Cologne, Germany)

    Objective: This study investigates the influence of levodopa (L-dopa) on tongue body movements during speaking. Background: Parkinson’s disease (PD) is a neurodegenerative disorder affecting non-motor…
  • MDS Virtual Congress 2020

    Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease

    C. Christine, R. Richardson, A. Van Laar, M. Thompson, K. Herbert, C. Li, G. Liang, E. Fine, P. Larson (San Francisco, CA, USA)

    Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…
  • MDS Virtual Congress 2020

    Effectiveness of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients with Moderate to Severe Fatigue: Sub-group Analysis from PROviDE study

    S. Isaacson, J. Aldred, D. Cella, P. Kandukuri, N. Gupta, Y. Jalundhwala, P. Kukreja, I. Pan, R. Pahwa (North Chicago, IL, USA)

    Objective: To examine the effect of CLES at 12 months of follow-up in APD patients with moderate to severe fatigue. Background: Fatigue, one of the…
  • MDS Virtual Congress 2020

    Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting

    S. Miri, S. Nakano, A. Carwin, M. Anjum, Y. Torres-Yaghi, F. Amjad, F. Pagan (Washington, DC, USA)

    Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…
  • MDS Virtual Congress 2020

    Nurse led intrajejunal levodopa pathway for a regional neurosciences centre

    P. Duggan-Carter, J. Cosgrove, J. Alty (Leeds, United Kingdom)

    Objective: To evaluate the impact of introducing a nurse led advanced therapy service for patients referred for levodopa/carbidopa intestinal gel (LCIG). Background: Leeds Teaching Hospitals…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley